Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Revitope logo — Powered for Precision: Revolutionizing immunotherapy to safe...

Revitope

Powered for Precision: Revolutionizing immunotherapy to safely and effectively treat more cancers

Founded 2016 United States Cambridge, United States 6 employees Series Unknown Total: $8.50M Biotechnology, Health Care +1

General Information

Company Name Revitope
Founded Year 2016
Location United States Cambridge, United States +1
Employees 6
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series Unknown
Social

Get notified when Revitope moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Revitope

Revitope, an early stage biotechnology company, is focused on revolutionizing immunotherapy to effectively treat a wide range of cancers. The company's Programmable Antibody Circuits (PACs) aim to redirect T cells to the surface of cancer cells, activating a potent immune response while expanding antigenic targeting space. Founded in 2014 in the United States, Revitope secured an $8.50M Venture Round investment on 08 February 2016. The company's innovative approach to immune-based therapies in cancer treatment positions it as a promising player in the Biotechnology and Health Care industries. Revitope's groundbreaking work in precision immunotherapy has the potential to significantly impact the future of cancer treatment.

Taxonomy: immunotherapy, cancer treatment, T cell redirecting biologics, precision medicine, immune-based therapies, programmable antibody circuits, immunodominant viral peptide, cancer immunotherapy, biologic prodrugs, antibody technology, oncology, clinical studies, viral immune response, antigenic targeting

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 08 Feb 2016

Revitope Alternatives & Competitors

Revitope vs
Tolerx, Inc.
Tolerx, Inc. United States

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candi...

Series Unknown
9 employees
Biotechnology, Health Care
Revitope vs
GeneMedicine
GeneMedicine Korea South

Biopharmaceutical company focusing on R&D and commercializing its oncolytic adenovirus platform for...

Series A
11 employees
Revitope vs
Novelogics Biotechnology Inc.
Novelogics Biotechnology Inc. Canada

Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer using an “In...

Angel
1 employees
Biotechnology, Health Care
Also compare with: Revitope vs 3T Biosciences 3T Biosciences

FAQ About Revitope

Powered for Precision: Revolutionizing immunotherapy to safely and effectively treat more cancers
Revitope was founded in 2016.
Revitope is headquartered in Cambridge, United States.
Revitope operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Revitope has approximately 6 employees.
Revitope has completed 1 funding round, raising a total of $8.50M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Revitope include Tolerx, Inc., GeneMedicine, Novelogics Biotechnology Inc., Acepodia, Imugene Limited. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Revitope and Tolerx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Revitope and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy